# The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020, Paragraph 155


In regulation 201 (amendment of Schedule 24 (packaging information requirements))—
(a) in paragraph (2), after “regulation 257D” insert “in the case of products for sale or supply in Great Britain, or in the case of products for sale or supply in Northern Ireland, any guidance published pursuant to Article 65 of the 2001 Directive or under regulation 257D that is applicable to such products.”;
(b) in paragraph (3), for “for “marketing authorisation”” to the end substitute “for “marketing authorisation,” substitute “UK marketing authorisation, EU marketing authorisation”.”;
(c) omit paragraph (4);
(d) in paragraph (5)—
(i) in the inserted Part 4 (outer and immediate packaging: advanced therapy medicinal products), in the heading, after “products” insert “for sale or supply in Great Britain only”;
(ii) in the inserted Part 5 (immediate packaging: blister packs and small packaging (advanced therapy medicinal products)), in the heading, after “products” insert “for sale or supply in Great Britain only”.

---
Source: https://www.legislation.gov.uk/ukdsi/2020/9780348213980/schedule/2/paragraph/155 (the official version)
Page: https://openlegislation.uk/draft-human-medicines-amendment-etc-eu-exit-regulations-2020/schedule-2/paragraph-155
Contains public sector information licensed under the Open Government Licence v3.0. Source: legislation.gov.uk, The National Archives.